A Study to Investigate Safety and Tolerability of TransCon IL-2 β/γ Alone or in Combination With Pembrolizumab and/or TransCon TLR7/8 Agonist or Other Anticancer Therapies in Adult Participants With Locally Advanced or Metastatic Solid Tumor Malignancies
ACTIVE_NOT_RECRUITING
Status
Conditions
- Advanced Solid Tumor
- Locally Advanced Solid Tumor
- Metastatic Solid Tumor
- Platinum-resistant Ovarian Cancer
- Post Anti-PD-1 Melanoma
- 2L+ Cervical Cancer
- Neoadjuvant Melanoma
- Neoadjuvant Non-Small Cell Lung Cancer
- Post Anti-PD-(L)1 Non-Small Cell Lung Cancer
- Post Anti-PD-(L)1 Small Cell Lung Cancer
- Third Line or Later (3L+) HER2+ Breast Cancer
- Second or Third Line (2L/3L) Cervical Cancer
- Third-line or Later (3L+) Platinum-resistant Ovarian Cancer (PROC)
Interventions
- DRUG: TransCon IL-2 β/γ
- DRUG: Pembrolizumab
- DRUG: Chemotherapy drug
- DRUG: TransCon TLR7/8 Agonist
- PROCEDURE: Surgery
- DRUG: Trastuzumab
- DRUG: Trastuzumab emtansine (T-DM1)
Sponsor
Ascendis Pharma Oncology Division A/S